ESMO 2022 | Challenges associated with implementing ctDNA approaches in melanoma

Georgina Long, BSc, PhD, MBBS, FRACP, FAHMS, The University of Sydney, Sydney, Australia, provides an overview of potential hurdles in utilizing circulating tumor DNA (ctDNA) to detect clinical progression in patients with melanoma. Whilst stratifying patients based on melanoma status, the sensitivity of current tests may impact the ability of ctDNA testing to monitor disease and treatment progression. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.